Mitochondria as cancer drug targets

被引：111

作者：

Don, AS

Hogg, PJ ^{[1
]}

机构：

[1] Univ New S Wales, Ctr Vasc Ctr, Sydney, NSW 2052, Australia

[2] Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia

来源：

TRENDS IN MOLECULAR MEDICINE | 2004年 / 10卷 / 08期

关键词：

D O I：

10.1016/j.molmed.2004.06.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cancer cells are defined by their unlimited replicative potential and resistance to cell death stimuli. It is generally considered that a point of no return in apoptotic cell death is the permeabilisation of the mitochondrial membranes. For this reason, agents that permeabilise cancer cell mitochondria have the potential to circumvent their resistance to apoptotic cell death. Fortunately, the proliferative and bioenergetic differences between normal and cancerous cells provide an opportunity to selectively target cancer cell mitochondria.

引用

收藏

页码：372 / 378

页数：7

相关论文

共 68 条

[1] Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial [J].

Amadori, D ;

Frassineti, GL ;

De Matteis, A ;

Mustacchi, G ;

Santoro, A ;

Cariello, S ;

Ferrari, M ;

Nascimben, O ;

Nanni, O ;

Lombardi, A ;

Scarpi, E ;

Zoli, W .

BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (03) :209-217

[2]

Amundson SA, 2000, CANCER RES, V60, P6101

[3] Targeting the prostate for destruction through a vascular address [J].

Arap, W ;

Haedicke, W ;

Bernasconi, M ;

Kain, R ;

Rajotte, D ;

Krajewski, S ;

Ellerby, HM ;

Bredesen, DE ;

Pasqualini, R ;

Ruoslahti, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) :1527-1531

[4]

Bahlis NJ, 2002, CLIN CANCER RES, V8, P3658

[5] PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism [J].

Banker, DE ;

Cooper, JJ ;

Fennell, DA ;

Willman, CL ;

Appelbaum, FR ;

Cotter, FE .

LEUKEMIA RESEARCH, 2002, 26 (01) :91-106

[6] Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437 [J].

Belzacq, AS ;

El Hamel, C ;

Vieira, HLA ;

Cohen, I ;

Haouzi, D ;

Métivier, D ;

Marchetti, P ;

Brenner, C ;

Kroemer, G .

ONCOGENE, 2001, 20 (52) :7579-7587

[7] ANTICARCINOMA ACTIVITY INVIVO OF RHODAMINE-123, A MITOCHONDRIAL-SPECIFIC DYE [J].

BERNAL, SD ;

LAMPIDIS, TJ ;

MCISAAC, RM ;

CHEN, LB .

SCIENCE, 1983, 222 (4620) :169-172

[8] Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: Final results of a phase III study with a factorial design [J].

Berruti, A ;

Bitossi, R ;

Gorzegno, G ;

Bottini, A ;

Alquati, P ;

De Matteis, A ;

Nuzzo, F ;

Giardina, G ;

Danese, S ;

De Lena, M ;

Lorusso, V ;

Farris, A ;

Sarobba, MG ;

DeFabiani, E ;

Bonazzi, G ;

Castiglione, F ;

Bumma, C ;

Moro, G ;

Bruzzi, P ;

Dogliotti, L .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4150-4159

[9] In vitro photodynamic properties of chalcogenopyrylium analogues of the thiopyrylium antitumor agent AA1 [J].

Brennan, NK ;

Hall, JP ;

Davies, SR ;

Gollnick, SO ;

Oseroff, AR ;

Gibson, SL ;

Hilf, R ;

Detty, MR .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (23) :5123-5135

[10] BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability [J].

Brimmell, M ;

Mendiola, R ;

Mangion, J ;

Packham, G .

ONCOGENE, 1998, 16 (14) :1803-1812

← 1 2 3 4 5 6 7 →